Literature DB >> 18305154

Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function.

Adrian W R Serohijos1, Tamás Hegedus, Andrei A Aleksandrov, Lihua He, Liying Cui, Nikolay V Dokholyan, John R Riordan.   

Abstract

Deletion of phenylalanine-508 (Phe-508) from the N-terminal nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR), a member of the ATP-binding cassette (ABC) transporter family, disrupts both its folding and function and causes most cystic fibrosis. Most mutant nascent chains do not pass quality control in the ER, and those that do remain thermally unstable, only partially functional, and are rapidly endocytosed and degraded. Although the lack of the Phe-508 peptide backbone diminishes the NBD1 folding yield, the absence of the aromatic side chain is primarily responsible for defective CFTR assembly and channel gating. However, the site of interdomain contact by the side chain is unknown as is the high-resolution 3D structure of the complete protein. Here we present a 3D structure of CFTR, constructed by molecular modeling and supported biochemically, in which Phe-508 mediates a tertiary interaction between the surface of NBD1 and a cytoplasmic loop (CL4) in the C-terminal membrane-spanning domain (MSD2). This crucial cytoplasmic membrane interface, which is dynamically involved in regulation of channel gating, explains the known sensitivity of CFTR assembly to many disease-associated mutations in CL4 as well as NBD1 and provides a sharply focused target for small molecules to treat CF. In addition to identifying a key intramolecular site to be repaired therapeutically, our findings advance understanding of CFTR structure and function and provide a platform for focused biochemical studies of other features of this unique ABC ion channel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305154      PMCID: PMC2265173          DOI: 10.1073/pnas.0800254105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors.

Authors:  Qais Al-Awqati
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  Aromatic-aromatic interactions and protein stability. Investigation by double-mutant cycles.

Authors:  L Serrano; M Bycroft; A R Fersht
Journal:  J Mol Biol       Date:  1991-03-20       Impact factor: 5.469

3.  Effect of cystic fibrosis-associated mutations in the fourth intracellular loop of cystic fibrosis transmembrane conductance regulator.

Authors:  J F Cotten; L S Ostedgaard; M R Carson; M J Welsh
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

4.  Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments.

Authors:  M Sharma; M Benharouga; W Hu; G L Lukacs
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

5.  Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity.

Authors:  F S Seibert; P Linsdell; T W Loo; J W Hanrahan; D M Clarke; J R Riordan
Journal:  J Biol Chem       Date:  1996-06-21       Impact factor: 5.157

6.  Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator.

Authors:  Hal A Lewis; Sean G Buchanan; Stephen K Burley; Kris Conners; Mark Dickey; Michael Dorwart; Richard Fowler; Xia Gao; William B Guggino; Wayne A Hendrickson; John F Hunt; Margaret C Kearins; Don Lorimer; Peter C Maloney; Kai W Post; Kanagalaghatta R Rajashankar; Marc E Rutter; J Michael Sauder; Stephanie Shriver; Patrick H Thibodeau; Philip J Thomas; Marie Zhang; Xun Zhao; Spencer Emtage
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

7.  Purification and crystallization of the cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  Mark F Rosenberg; Alhaji Bukar Kamis; Luba A Aleksandrov; Robert C Ford; John R Riordan
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

8.  Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  C E Bear; C H Li; N Kartner; R J Bridges; T J Jensen; M Ramjeesingh; J R Riordan
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

9.  Nucleotide-binding domains of human cystic fibrosis transmembrane conductance regulator: detailed sequence analysis and three-dimensional modeling of the heterodimer.

Authors:  I Callebaut; R Eudes; J-P Mornon; P Lehn
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

10.  Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein.

Authors:  Joseph K Zolnerciks; Carol Wooding; Kenneth J Linton
Journal:  FASEB J       Date:  2007-07-12       Impact factor: 5.191

View more
  196 in total

1.  Differential contribution of TM6 and TM12 to the pore of CFTR identified by three sulfonylurea-based blockers.

Authors:  Guiying Cui; Binlin Song; Hussein W Turki; Nael A McCarty
Journal:  Pflugers Arch       Date:  2011-12-13       Impact factor: 3.657

2.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR.

Authors:  Andrei A Aleksandrov; Pradeep Kota; Liying Cui; Tim Jensen; Alexey E Alekseev; Santiago Reyes; Lihua He; Martina Gentzsch; Luba A Aleksandrov; Nikolay V Dokholyan; John R Riordan
Journal:  J Mol Biol       Date:  2012-03-08       Impact factor: 5.469

Review 3.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

4.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity.

Authors:  Xuehong Liu; Nicolette O'Donnell; Allison Landstrom; William R Skach; David C Dawson
Journal:  Biochemistry       Date:  2012-06-15       Impact factor: 3.162

5.  Dynamics of a bacterial multidrug ABC transporter in the inward- and outward-facing conformations.

Authors:  Shahid Mehmood; Carmen Domene; Eric Forest; Jean-Michel Jault
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

6.  Functional rescue of a misfolded eukaryotic ATP-binding cassette transporter by domain replacement.

Authors:  Raymond J Louie; Silvere Pagant; Ji-Young Youn; John J Halliday; Gregory Huyer; Susan Michaelis; Elizabeth A Miller
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

7.  Intragenic suppressing mutations correct the folding and intracellular traffic of misfolded mutants of Yor1p, a eukaryotic drug transporter.

Authors:  Silvere Pagant; John J Halliday; Christos Kougentakis; Elizabeth A Miller
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

8.  A posttranslational modification code for CFTR maturation is altered in cystic fibrosis.

Authors:  Sandra Pankow; Casimir Bamberger; John R Yates
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

9.  Cooperative assembly and misfolding of CFTR domains in vivo.

Authors:  Kai Du; Gergely L Lukacs
Journal:  Mol Biol Cell       Date:  2009-01-28       Impact factor: 4.138

Review 10.  Ion Channel Modulators in Cystic Fibrosis.

Authors:  Martina Gentzsch; Marcus A Mall
Journal:  Chest       Date:  2018-05-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.